ArticleAntimicrobial agents and chemotherapy2013
Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Antimicrobial agents and chemotherapy · 2016Trial
- Molecular Mechanisms, Diagnosis, and Therapeutic Strategies of Antifungal Resistance in Filamentous Fungi.Journal of fungi (Basel, Switzerland) · 2026Review
- Voriconazole Activity AgainstMolecules (Basel, Switzerland) · 2026Article
- Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris.Mycopathologia · 2024Article
- Antifungal Resistance and the Role of New Therapeutic Agents.Current infectious disease reports · 2022Review
- Resistance to Echinocandins Complicates a Case ofJournal of fungi (Basel, Switzerland) · 2021Article
- In vitro activity of isavuconazole against clinically isolated yeasts from Chile.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- Colistin and Isavuconazole Interact Synergistically In Vitro againstMicroorganisms · 2020Article
- In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus againstJournal of fungi (Basel, Switzerland) · 2020Article
- Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.Mycopathologia · 2020Article
- EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.Antimicrobial agents and chemotherapy · 2019Article
- Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance inAntimicrobial agents and chemotherapy · 2019Article
- EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.Antimicrobial agents and chemotherapy · 2019Article
- Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.Journal of clinical microbiology · 2018Article
- Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2018Review
- Impact of Homologous Resistance Mutations from Pathogenic Yeast on Saccharomyces cerevisiae Lanosterol 14α-Demethylase.Antimicrobial agents and chemotherapy · 2018Article
- The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.Current infectious disease reports · 2018Review
- Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China.Emerging microbes & infections · 2017Article
- Development and Validation of a High-Resolution Melting Assay To Detect Azole Resistance in Aspergillus fumigatus.Antimicrobial agents and chemotherapy · 2017Article
- Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole.Medical mycology case reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isavuconazole is a novel expanded-spectrum triazole, which has recently been approved by the FDA as an orphan drug to treat invasive aspergillosis and is currently being studied in phase III clinical trials for invasive candidiasis. The susceptibility of relatively few clinical isolates has been reported. In this study, the isavuconazole susceptibilities of 1,237 Aspergillus and 2,010 Candida geographically diverse clinical isolates were determined by EUCAST methodology at four European mycology laboratories, producing the largest multicenter data set thus far for this compound. In addition, a blinded collection of 30 cyp51A mutant Aspergillus fumigatus clinical isolates and 10 wild-type isolates was tested. From these two data sets, the following preliminary epidemiological cutoff (ECOFF) values were suggested: 2 mg/liter for Aspergillus fumigatus, Aspergillus terreus, and Aspergillus flavus; 4 mg/liter for Aspergillus niger; 0.25 mg/liter for Aspergillus nidulans; and 0.03 mg/liter for Candida albicans, Candida parapsilosis, and Candida tropicalis. Unfortunately, ECOFFs could not be determined for Candida glabrata or Candida krusei due to an unexplained interlaboratory MIC variation. For the blinded collection of A. fumigatus isolates, all MICs were ≤2 mg/liter for wild-type isolates. Differential isavuconazole MICs were observed for triazole-resistant A. fumigatus isolates with different cyp51A alterations: TR34/L98H mutants had elevated isavuconazole MICs, whereas isolates with G54 and M220 alterations had MICs in the wild-type range, suggesting that the efficacy of isavuconazole may not be affected by these alterations. This study will be an aid in interpreting isavuconazole MICs for clinical care and an important step in the future process of setting official clinical breakpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.